Organogenesis Graftskin shows 61% complete wound closure rate in clinicals.
This article was originally published in The Gray Sheet
Executive Summary
ORGANOGENESIS GRAFTSKIN 61% COMPLETE WOUND CLOSURE RATE in venous ulcer patients compares favorably to a 44% rate observed in patients in a control group, the company said. On May 2, Organogenesis announced results from its 300-patient, multicenter Phase III pivotal clinical trial of the Graftskin manufactured human skin product.